1. $630m cash(now cd be $680m) - Why can't we acquire marketed or late stage assets ?
Sun's ex-Taro cash position is lower but yet, Sun has been doing this very aggressively...Dusa, Url, Ranbaxy .
2. Rest of World market potential for Taro's 190 products. Why is this not being exploited ?
3. Why can't we conduct an earnings conf call and be accountable to all shareholders at large ?